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strial fibrillation remains a challenge to manage. Although
here are issues concerning rate and rhythm control, pre-
ention of thromboembolism remains the most important
spect of management. Untreated, strokes will occur in
bout 2% to 5% of patients per year, and the strokes caused
y atrial fibrillation can be quite devastating (1,2). Although
ew pharmacologic and nonpharmacologic approaches to
revention of thromboembolism have been subjects of
ntense investigation, treatment with warfarin remains the
ornerstone of therapy. This is true despite the well-known
imitations of warfarin, and remains true because warfarin is
ffective and can be expected to reduce the incidence of
hromboembolism by about two-thirds.
See page 810
Warfarin has several problems that limit the enthusiasm
f clinicians: there is a narrow therapeutic window, there are
ultiple drug and food interactions, there is genetic vari-
bility in response, the half-life is long, and it increases the
ncidence of bleeding. Therefore, it would appear wise to try
o identify patients at sufficiently low risk of thromboem-
olism or sufficiently high risk of complications of warfarin
o that warfarin would not be used. This was investigated by
ang et al. (3) using the ATRIA (AnTicoagulation and
isk Factors In Atrial Fibrillation) study cohort. This
ohort is composed of 13,559 adults with atrial fibrillation,
ith a median follow-up of 6 years. The study considered
0,932 patients who were off of warfarin for some period of
ime and also 5,588 patients who were not on warfarin at
aseline and had at least a 12-month fixed period off of
arfarin. Events were adjudicated by committee. Five dif-
erent stratification schemes were investigated: the Atrial
ibrillation Investigators, Stroke Prevention in Atrial Fi-
rillation, Congestive heart failure, Hypertension, Age 75
ears, Diabetes mellitus, and prior Stroke or transient
schemic attack score, Framingham Score, and 7th Ameri-
an College of Chest Physicians Conference on Antithrom-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thea
merican College of Cardiology.
From the Christiana Care Health System, Newark, Delaware.otic and Thrombolytic Therapy (ACCP) guidelines. For
ach scheme the patients were grouped as low risk, inter-
ediate risk, or high risk. The prevalence of low risk varied
rom 11.7% with 7th ACCP to 37.1% with Framingham
nd high risk from 16.4% with Framingham and 80.4%
ith 7th ACCP. The annualized thromboembolism rate in
he low-risk group varied from 0.13% with 7th ACCP to
.81% with Framingham. The annualized thromboembo-
ism rate in the high-risk group varied from 2.5% with 7th
CCP to 3.9% with Framingham.
The performance of the risk schemes was evaluated with
he c index. The c index evaluates the discrimination of
rediction models; thus, the c index is the faction of pairs of
atients, 1 with and 1 without an event, where the one with
he event will have a higher probability of the event
ccurring based on the model. A c index of 0.5 means that
here is no ability to discriminate and a c index of 1 means
erfect discrimination. This study showed c indexes of 0.60
o 0.69 in the group with no warfarin at baseline. This
uggests that discrimination is fair at best. Nonetheless, the
odels could be viewed as calibrating better than discrim-
nating. Calibration refers to how well a model’s prediction
f risk correlates with observed risk. Here the results were
ot so bad, and risk varied from 0.13% in low-risk 7th
CCP to 2.5% in high-risk 7th ACCP. It should be noted
hat calibration and discrimination are not the same thing
nd that models with perfect calibration have an upper limit
f discrimination (4).
Overall, this study is well done and carefully analyzed.
here are several limitations that the investigators recog-
ize. It is not possible or ethical to keep patients off of
arfarin. Thus to assess natural history, it is necessary to
ither follow up patients during periods off of warfarin or
ollow up patients who do not or cannot take warfarin. This
ay provide a population that is not entirely characteristic
f all patients with atrial fibrillation. Also, it was not
ossible to assess aspirin usage, which may have lowered the
hromboembolism rate somewhat. There are also limita-
ions to the database in that blood pressure and left
entricular function were not assessed. This resulted in
everal of the scores being approximations rather than exact
ssessments using the scores as published.
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February 26, 2008:816–7 Editorial CommentThe primary finding of this study is that although models
redict a spectrum of risk, it is hard to say in any one patient
hether they will or will not suffer an event. Given the
atastrophic outcome of stroke in patients with atrial fibril-
ation as well as the efficacy of warfarin, it remains the
tandard of care to treat almost everyone (1,5). What level of
isk might be considered so low that warfarin might not be
sed? This is actually beyond the scope of the present study;
his issue could, in principle, be approached with cost-
ffectiveness analysis. However, in all patients in whom
here is net clinical benefit to warfarin, at least on clinical
rounds it should be used. The low-risk group identified by
ang et al. (3) with ACCP, with a risk of 0.13% per year,
ight qualify. These are patients younger than age 65 with
o identified risk factors, a reasonable group to consider not
nticoagulating. However, this was only 11.7% of the
opulation.
So, for now, most patients with atrial fibrillation will be
nticoagulated, saving those at very low risk and patients
ho for one reason or another cannot or will not take
arfarin. Is there any difference between permanent, per-
istent, and paroxysmal atrial fibrillation? The risk of stroke
s increased in all 3 types of atrial fibrillation, and generally
he type of atrial fibrillation is not considered (2). However,
here are always exceptional cases. Does the patient present-
ng with a first-ever episode who spontaneously converts
eed to be anticoagulated? Does anticoagulation always
eed to be for life? If a patient has been in sinus rhythm for
 years with no palpitations, can he or she come off
arfarin? Although this may seem reasonable, it is not
ossible to be sure that the patient was not having silent
pisodes of atrial fibrillation. When does the risk of falls and
ead injury become too great and thus the competing risk of
mbolic stroke become acceptable?
The end result is that atrial fibrillation management will
emain challenging, with difficult medical decision making
hat may not be adequately assessed by guidelines. Fang
t al. (3) stress the need for more detailed models with better
bility to discriminate which patients will suffer a throm-
otic event. There is also a need for better pharmacotherapy,
ffering less complicated management than warfarin; this is
 subject of intense interest by the pharmaceutical industry.
inally there is need for reliable, durable approaches toaintaining sinus rhythm. It is not a given that mainte-
ance of sinus rhythm will translate into reduced stroke risk.
he stroke risk was actually high in the rhythm control arm
f the AFFIRM (Atrial Fibrillation Follow-up Investi-
ation of Rhythm Management) study (6 ). Approxi-
ately one-half of the patients who are converted to
inus rhythm can be expected to have recurrent atrial
brillation within 1 year (7). Thus, we still lack a reliable
harmacologic or procedural approach to establishing and
aintaining sinus rhythm. When such an approach be-
omes available, it will still be necessary to prove that
atients are not at a level of risk of thromboembolism that
ould still warrant anticoagulation.
So, the challenge of atrial fibrillation management con-
inues. Most of our patients will be on warfarin, mostly for
long time.
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